灵芝孢子粉对中重度慢性阻塞性肺疾病的随访研究

doi:10.3969/j.issn.1000-8535.2020.02.004

摘要/Abstract

摘要： 目的观察灵芝孢子粉对中重度慢性阻塞性肺疾病(COPD)稳定期患者肺功能、6分钟步行距离及T淋巴细胞亚群的影响。方法选取稳定期中重度COPD门诊患者19例,服用灵芝孢子粉6个月后观察患者服药前后肺功能的变化及循环血液中CD4⁺、CD8⁺T淋巴细胞的比例变化,症状评分(CAT评分)以及对6 MWT的影响。结果服用灵芝孢子粉6个月后,中重度COPD患者的六分钟步行距离延长,平均增加19 m(P＜0.01),患者的CAT评分也有改善(P＜0.01),患者肺功能与服药前相比有改善趋势,其中FEV₁较服用前平均增加60 mL(P>0.05),FVC平均增加为130 mL(P<0.01),FEV₁/FVC比例降低0.47(P>0.05);外周血CD4⁺T淋巴细胞比例增加(P<0.01),CD8⁺和CD4⁺/CD8⁺T淋巴细胞亚群比例未见明显变化(P＞0.05)。结论服用灵芝孢子粉6个月后对肺功能无明显作用,但能改善中重度COPD患者的CAT症状评分,可能与升高CD4⁺T淋巴细胞比例有关。

关键词: 灵芝孢子粉, COPD, 肺功能, CD4⁺, CD8⁺

Abstract: Objective To observe the effects of Ganoderma lucidum spore powder on lung function, 6-minute walking distance and T lymphocyte subsets in patients with moderate to severe chronic obstructive pulmonary disease(COPD). Methods Nineteen patients with moderate-to-severe COPD outpatients in stable phase were enrolled. After taking Ganoderma lucidum spore powder for 6 months, the changes of lung function and the proportion of CD4⁺ and CD8⁺ T lymphocytes in circulating blood, the symptom score(CAT score) and impact on the 6 MWT were observed. Results After taking Ganoderma lucidum spore powder for 6 months, the six-minute walking distance of patients with moderate to severe COPD was prolonged, with an average increase of 19 meters(P<0.01). The patient's CAT score was also improved(P<0.01). There was an improvement trend in increasing average FEV1 by 60 mL(P>0.05), FVC increased to 130 mL(P<0.01) and the FEV1/FVC ratio decreased by 0.47(P>0.05). The proportion of CD4⁺ T lymphocytes in peripheral blood increased(P<0.01), and the proportion of CD8⁺ and CD4⁺/CD8⁺ T lymphocyte subsets did not reach the significance(P>0.05). Conclusion After taking Ganoderma lucidum spore powder for 6 months, it has no significant effect on lung function, but it may improve the CAT symptom score of patients with moderate to severe COPD, which may be related to the increase of CD4⁺ T lymphocyte ratio.

Key words: Ganoderma lucidum spore powder, COPD, Pulmonary function, CD4⁺, CD8⁺

冼慧仪, 冯曙平, 陈艳, 吴凡, 李风雷. 灵芝孢子粉对中重度慢性阻塞性肺疾病的随访研究[J]. 广州医药, 2020, 51(2): 15-20.

XIAN Huiyi, FENG Shuping, CHEN Yan, WU Fan, LI Fenglei. The clinical outcome of Ganoderma lucidum spore powder for moderate or severe chronic obstructive pulmonary disease patients[J]. Guangzhou Medical Journal, 2020, 51(2): 15-20.

参考文献

[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版) [J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[2] WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health [CPH]study): a national cross-sectional study [J]. Lancet, 2018, 391(10 131): 1706-1717.
[3] BAUGHMAN P, MAROTT J L, LANGE P, et al. Combined effect of lung function level and decline increases morbidity and mortality risks [J]. Eur J Epidemiol, 2012, 27(12): 933-943.
[4] WILLIAMS J, STAFFORD E, WILLIAMS K, et al. Managing hospitalized patients with chronic obstructive pulmonary disease [J]. JAAPA, 2014, 27(12): 18-22.
[5] KOCH K, GACZKOWSKI M, STURTON G, et al. Modification of surface antigens in blood CD8⁺ T-lymphocytes in COPD: effects of smoking [J]. Eur Respir,2007, 29(1): 42-50.
[6] VERNOOY J H, DENTENER M A, VAN SUYLEN R J, et al. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology [J]. Am J Respir Cell Mol Biol, 2002, 26(1): 152-159.
[7] 刘华, 唐琼. 中药灵芝药理作用研究 [J]. 中国医药导报, 2009, 6(5): 153-154.
[8] 姜芳燕, 马军, 陈永敢, 等. 灵芝活性成分的研究进展 [J]. 黑龙江农业科学, 2014(8): 137-142.
[9] KOYA T, MIYAHARA N, TAKEDA K, et al. CD8+ T cell-mediated airway hyperresponsiveness and inflammation is dependent on CD4+IL-4+ T cells [J]. J Immunol, 2007, 179(5): 2787-2796.
[10] TARIQ A B. Immune Dysfunction in Patients with chronic obstructive pulmonary disease [J]. Ann Am Thorac Soc, 2015, 12 Suppl(2): S169-75.
[11] MCKENDRY R T, SPALLUTO C M, BURKE H, et al. Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. role of the PD-1-PD-L1 Axis [J]. Am J Respir Crit Care Med, 2016, 193(6): 642.
[12] MATHAI R T K, SMITHA B. Peripheral Blood T-Cell Populations in COPD, Asymptomatic Smokers and Healthy Non-Smokers in Indian subpopulation-a pilot study [J]. J Clin Diagn Res, 2013, 7(6): 1109-1113.
[13] 廖长征, 徐文莉, 陈思祖. 慢性阻塞性肺疾病患者外周血T淋巴细胞凋亡检测的临床价值 [J]. 检验医学, 2015, 30(10): 971-974.
[14] 王成阳, 刘向国, 彭青和, 等. 调节性T细胞、辅助T细胞在慢性阻塞性肺疾病患者肺功能降低中的作用 [J]. 中国老年学杂志, 2014(22): 6247-6249.
[15] ZHUO S, LI N, ZHENG Y, et al. Expression of the lymphocyte chemokine xcl1 in lung tissue of COPD mice, and its relationship to CD4(+)/CD8(+) ratio and IL-2 [J]. Cell Biochem Biophys, 2015, 73(2): 505-511.
[16] GOLPE R, PEREZ-DE-LLANO L A, MENDEZ M, et al. Prognostic value of walk distance, work, oxygen saturation, and dyspnea during 6-minute walk test in COPD patients [J]. Respir Care, 2013, 58(8): 1329-1334.
[17] BAK S H, KWON S O, HAN S S, et al. Computed tomography-derived area and density of pectoralis muscle associated disease severity and longitudinal changes in chronic obstructive pulmonary disease: a case control study [J]. Respir Res, 2019, 20(1): 226.
[18] BARNES P J, CELLI B R. Systemic manifestations and comorbidities of COPD [J]. Eur Respir J, 2009, 33(5): 1165-1185.
[19] HOGG J C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease [J]. Lancet, 2004, 364(9435): 709-721.
[20] BARNES P J. Immunology of asthma and chronic obstructive pulmonary disease [J]. Nature Rev Immunol, 2008, 8(3): 183-192.
[21] HABIJANIC J, BEROVIC M, BOH B, et al. Submerged cultivation of Ganoderma lucidum and the effects of its polysaccharides on the production of human cytokines TNF-alpha, IL-12, IFN-gamma, IL-2, IL-4, IL-10 and IL-17 [J]. N Biotechnol, 2015, 32(1): 85-95.
[22] 张荣标, 陈润, 陈冠敏, 等. 破壁灵芝孢子粉对小鼠免疫功能影响的研究 [J]. 预防医学论坛, 2013(12): 936-938.
[23] 易有金, 胡瞬, 熊兴耀, 等. 灵芝孢子油对免疫低下模型小鼠的免疫调节作用 [J]. 浙江大学学报(农业与生命科学版), 2013(2): 161-166.
[24] 周吉华, 张庆华. 灵芝孢子对老年宫颈癌患者外周血T淋巴细胞亚群及VEGF的影响 [J]. 中国妇幼保健, 2014, 29(13): 2021-2022.
[25] SAETTA M, DI STEFANO A, TURATO G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 1998, 157(3 Pt 1): 822-826.
[26] CURTIS J L, FREEMAN C M, HOGG J C. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research [J]. Proceedings Am Thorac Soc, 2007, 4(7): 512-521.
[27] HOGG J C, CHU F, UTOKAPARCH S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease [J]. N Engl J Med, 2004, 350(26): 2645-2653.